Stenocare AS (FRA:S7C) Interest Expense: €-0.08 Mil (TTM As of Mar. 2026)


FRA:S7C Stenocare AS FRA:S7C
40 GF Score
Price €0.13
GF Value €0.29
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Stenocare AS Interest Expense?

Stenocare AS FRA:S7C 40 Interest Expense is €-0.08 Mil as of Mar. 2026. GuruFocus rates FRA:S7C with a GF Score™ of 40/100 and a GF Value™ of €0.29 (Possible Value Trap). The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Stenocare AS's interest expense for the three months ended in Mar. 2026 was € -0.02 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.08 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Stenocare AS's Operating Income for the three months ended in Mar. 2026 was € -0.05 Mil. Stenocare AS's Interest Expense for the three months ended in Mar. 2026 was € -0.02 Mil. Stenocare AS did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Stenocare AS  (FRA:S7C) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Stenocare AS's Interest Expense for the three months ended in Mar. 2026 was €-0.02 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-0.05 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €0.00 Mil.

Stenocare AS's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Stenocare AS did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Stenocare AS Interest Expense Historical Data

* Premium members only.

The historical data trend for Stenocare AS's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stenocare AS Interest Expense Chart

Stenocare AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -0.03 -0.17 -0.39 -0.21 -0.09

Stenocare AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.02 -0.02 -0.02 -0.02
FRA:S7C
40GF Score
Stenocare AS FRA:S7C
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stenocare AS Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.08 Mil mean?
Stenocare AS (FRA:S7C) has a Interest Expense of €-0.08 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Stenocare AS and its competitors.
Is Stenocare AS's Interest Expense too high?
Stenocare AS's current Interest Expense is €-0.08 Mil. Overall, Stenocare AS has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Stenocare AS's Interest Expense compare to ZTS and UTHR?
Stenocare AS's Interest Expense of €-0.08 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Stenocare AS and its competitors. Stenocare AS's current Interest Expense is €-0.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stenocare AS stock overvalued right now?
Based on GuruFocus' analysis, Stenocare AS (FRA:S7C) is currently considered Possible Value Trap. The stock's GF Value™ is €0.29, compared to a current price of €0.13 — trading 56.9% below its estimated fair value. The current Interest Expense is €-0.08 Mil. Stenocare AS's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Stenocare AS (FRA:S7C), the current Interest Expense is €-0.08 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stenocare AS (FRA:S7C) Overvalued in 2026?

Based on GuruFocus' analysis, Stenocare AS stock appears to be undervalued. The current stock price of €0.13 is trading 56.9% below its estimated GF Value™ of €0.29. GuruFocus considers Stenocare AS to be Possible Value Trap.

Key valuation signals for FRA:S7C:

  • Interest Expense: €-0.08 Mil
  • GF Value™: €0.29 vs. price of €0.13 (56.9% below fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the FRA:S7C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Stenocare AS Business Description

Other Exchanges STENO:Denmark
Address Lejrvej 9, Vaerlose, DNK, 93500
Stenocare AS is a Danish company engaged in the cultivation and production of medical cannabis products through pharmacies and hospitals. The company's business operations include the distribution and sales of imported products to several markets which also includes local cultivation and production of its medical cannabis products. Stenocare is well positioned to become a market leader in Denmark and a vendor in Europe. The company is a supplier of medical cannabis oil for patients in Denmerk, Sweden, UK, Australia and Norway.
40GF Score

Get the complete analysis for FRA:S7C

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.13
Price
€0.29
GF Value